Natco Pharma Limited has informed the Exchange about press release dated 07-Mar-2022 titled NATCO Announces Launch of the First Generic Version of Revlimid�� (Lenalidomide capsules), in the U.S. market
Press Release Mar 07 2022
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from NATCO Pharma
- NATCO announces License Agreement with the Medicines Patent Pool
- Press Release Jan 20 2022
- Press Release Jan 07 2022
- Press Release Jan 01 2022
- NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India
Later from NATCO Pharma
- NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
- Press Release Jun 01 2022
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jul 25 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma